Patient-operated imaging for clinical assessment: regulatory and reimbursement challenges in European health systems

Patient-operated medical technologies are increasingly integrated into European care. Under EU regulation, CE marking confirms safety and performance for each specific intended use, while reimbursement requires separate demonstration of clinical and economic value. Imaging has historically differed because acquisition and interpretation are typically coupled within the same clinical encounter.

To examine patient-operated imaging for clinical assessment (POICA) as a regulatory and reimbursement boundary case under the EU Medical Device Regulation (MDR), and to analyse how redistribution of image acquisition to patients, while preserving clinician-led interpretation, challenges regulatory classification, liability allocation, and reimbursement models historically built around a unified professional imaging act.

We conducted a structured policy and regulatory analysis examining how patient-operated imaging interacts with existing European regulatory and reimbursement frameworks. Sources were selected based on their relevance to decentralized acquisition, clinical reliability, workflow organization, and reimbursement integration. The analysis integrates MDR and Medical Device Coordination Group (MDCG) guidance documents, usability and risk-management standards), liability principles for home-use medical devices, and the structure of European health technology assessment (HTA) and reimbursement systems. Patient-operated imaging was evaluated against precedents in which elements of technical execution moved outside institutional settings (e.g., self-testing in vitro diagnostics, home-based therapies, and remote monitoring models) to identify where existing frameworks accommodate decentralized image acquisition and where structural tensions arise.

Imaging, even in structured monitoring contexts such as fertility care, requires each acquisition to meet clinical adequacy thresholds at the time of interpretation. This creates acquisition-dependent risk that cannot be mitigated through repetition alone. Under the MDR, adequacy criteria and the mechanisms ensuring them must be explicit; usability validation must demonstrate interpretative reliability rather than procedural completion. Responsibility becomes hybrid, with patients performing acquisition while clinicians retain interpretive and clinical decision-making authority. Economically, this redistribution disrupts reimbursement models built around a single bundled professional imaging act.

The central challenge is not regulatory authorization but maintaining clinical reliability when acquisition is decentralized. Integration into European health systems will depend on demonstrable reliability of patient-acquired images, clear allocation of responsibility, and reimbursement mechanisms capable of recognizing distributed clinical workflows, while maintaining alignment between physician incentives and high-quality care.